$RXRX · RECURSION PHARMACEUTICALS, INC.

Recursion Pharmaceuticals filed its 10-Q for the quarter ended September 30, 2026. Total revenue surged to $18.6M (+258.5% YoY), driven by operating revenue from strategic alliances. Net loss narrowed to $(119.0M) or $(0.22) per share from $(162.3M) or $(0.36) per share a year ago. Operating expenses declined 20% YoY to $141.7M. Cash and equivalents were $549.9M at quarter-end. A subsequent event notes the October 16, 2026 sale of 61.5M shares for net proceeds of approximately $187.2M.

Extended-hours last trade at $3.82, down 0.26% from regular close of $3.83. The modest after-hours drift suggests the Q3 beat on revenue and narrower loss was largely priced in or offset by the dilutive $187.2M equity raise disclosed as a subsequent event.

Recursion's 258% revenue growth and sharply narrower losses show its AI-drug-discovery model gaining traction, but the immediate post-quarter $187M dilutive raise tempers the bullish signal.

Recursion's AI-driven drug discovery model continues to show operating leverage, with expenses declining across all categories while revenue scales. The post-quarter equity raise mirrors a broader biotech trend of pre-emptive capital raises to extend runway amid still-negative cash flows.

Cash burn remains significant: $549.9M in cash at quarter-end plus $187.2M from the October offering must fund ongoing operating losses ($367.5M net loss over nine months). The company cites a reasonable possibility of releasing a valuation allowance within 12 months, which would signal a return to profitability — but timing is uncertain.